Aflibercept: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Aflibercept": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 27: | Line 27: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
==Overview== | ==Overview== | ||
Revision as of 20:47, 8 August 2012
| Identifiers | |
|---|---|
| |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C4318H6788N1164O1304S32 |
| Molar mass | 96,898.57 g·mol−1 |
Overview
Aflibercept is a fusion protein under development for the treatment of cancer.
Aflibercept is being co-developed by Sanofi-Aventis and Regeneron Pharmaceuticals. As of 2008, it is currently in phase III clinical trials.
Categories:
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Monoclonal antibodies
- Engineered proteins